Needham lowered the firm’s price target on Merit Medical (MMSI) to $116 from $122 but keeps a Buy rating on the shares after its Q4 earnings beat. Organic revenue growth improved, free cash flow remained strong, and the company continues to execute well on its strategy while anticipating sustained strong revenue growth, margin improvement, and free cash flow, the analyst tells investors in a research note. Needham adds however that it is reducing its FY26 EPS view by 19c to $4.00.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical price target lowered to $127 from $128 at Canaccord
- Strong Growth and Positive Outlook Drive Buy Rating for Merit Medical Systems Despite EPS Challenges
- Merit Medical price target lowered to $117 from $120 at Wells Fargo
- Strong Financial Performance and Strategic Execution Drive Buy Rating for Merit Medical Systems
- Merit Medical Reports Strong 2024 Financial Results